Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M45.8Revenue $M0.2Net Margin (%)-8,388.1Z-Score-7.5
Enterprise Value $M28.4EPS $-0.1Operating Margin %-9,294.3F-Score6
P/E(ttm))0Cash Flow Per Share $-0.1Pre-tax Margin (%)-8,388.1Higher ROA y-yY
Price/Book1.810-y EBITDA Growth Rate %0Quick Ratio4.2Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-8.3Current Ratio4.2Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-46.5Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-54.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M200ROI % (ttm)-49.0Gross Margin Increase y-yY

Gurus Latest Trades with HEB

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HEBArnold Schneider 2007-03-31 Sold Out $1.65 - $2.31
($2)
$ 0.24-88%Sold Out0
HEBArnold Schneider 2006-12-31 Buy $1.96 - $2.34
($2.1)
$ 0.24-89%New holding, 10000 sh.10,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HEB is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


HEB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STRAYER DAVID RMedical Director 2012-05-18Buy50,000$0.26-7.69view
Lander Russel JVP of Process/QualityAssurance 2011-03-01Buy50,000$0.46-47.83view
Lander Russel JVP of Process/QualityAssurance 2010-08-23Buy4,910$0.51-52.94view
CARTER WILLIAM ACEO, 10% Owner 2010-08-10Sell377,388$0.49-51.02view
STRAYER DAVID RMedical Director 2010-06-23Sell50,900$0.55-56.36view
STRAYER DAVID RMedical Director 2010-06-16Buy230,586$0.57-57.89view
Bernhardt Charles Thomas IIICFO 2010-06-15Sell87,794$0.59-59.32view
Springate Wayne S.Vice President of Operations 2010-06-15Sell83,104$0.59-59.32view
CARTER WILLIAM ACEO, 10% Owner 2010-06-11Buy500,000$0.66-63.64view
Springate Wayne S.Vice President of Operations 2009-12-15Buy877$0.56-57.14view

Press Releases about HEB :

    Quarterly/Annual Reports about HEB:

    News about HEB:

    Articles On GuruFocus.com
    Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
    Hemispherx Biopharma Inc Reports Operating Results (10-K/A) Feb 14 2011 
    Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
    Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
    Hemispherx Biopharma Inc Reports Operating Results (10-Q) Nov 08 2010 
    Weekly CEO Sells Highlight: Hemispherx Biopharma Inc, ADESA Inc, Entergy Corp, and Danaher Corp. Aug 15 2010 
    Hemispherx Biopharma Inc Reports Operating Results (10-Q) Aug 06 2010 
    Hemispherx Biopharma Inc (HEB) CEO William A Carter buys 500,000 Shares Jul 01 2010 
    Weekly CFO Buys Highlight: Wireless Telecom Group, ValueVision Media, American River Bankshares, Hem Dec 12 2009 
    Hemispherx Biopharma Inc (HEB) CFO Charles Thomas Iii Bernhardt buys 2,000 Shares Dec 08 2009 

    More From Other Websites
    Hemispherx Biopharma Announces the Completion of the Newly Upgraded Alferon(R) Facility: Commercial... Mar 02 2015
    Hemispherx Biopharma: Institute of Medicine, the Health Arm of the US National Academy of Sciences... Feb 23 2015
    Hemispherx Biopharma: Institute of Medicine, the Health Arm of the US National Academy of Sciences... Feb 23 2015
    Hemispherx Biopharma and USAMRIID to Present New Discoveries Concerning the Efficacy of Ampligen®... Feb 12 2015
    Hemispherx Biopharma and USAMRIID to Present New Discoveries Concerning the Efficacy of Ampligen(R)... Feb 12 2015
    Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen(R) Produced 100% Survival Rate... Feb 09 2015
    U.S. Army Medical Researchers to Hemispherx: We're Really Not That Into You Feb 04 2015
    Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate in Ebola... Feb 02 2015
    USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments Jan 26 2015
    Hemispherx Biopharma Awarded $770,852 by Federal Judge Jan 15 2015
    Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum... Jan 12 2015
    Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum Jan 12 2015
    Arrowhead Issues Diligence and Valuation Report on Hemispherx Biopharma Jan 09 2015
    Hemispherx’s Ampligen® Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint... Dec 16 2014
    Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint... Dec 16 2014
    Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen® Enlarged by Howard University... Dec 09 2014
    Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen(R) Enlarged by Howard University... Dec 09 2014
    HEMISPHERX BIOPHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers Nov 18 2014
    HEMISPHERX BIOPHARMA INC Financials Nov 18 2014
    Hemispherx Biopharma Reports on Annual Stockholder Meeting Nov 14 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK